A phase 3, randomized, open-label study of the anti-Globo H vaccine adagloxad simolenin/obi-821 in the adjuvant treatment of high-risk, early-stage, Globo H-positive triple-negative breast cancer.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, IDCQ Hospitales y Sanidad, S.L.U., Universidad Europea de Madrid, Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, National Taiwan University Hospital, Asan Medical Center, University of Ulsan, University of Chicago Medical Center, University of Kansas Medical Center, University of California San Diego
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4281982547